Don't mistake Stryker's latest $500 million deal in the spine market as a simple tuck-in acquisition, says one analyst while another says it could help Stryker give Medtronic a run for its money.
The acquisition price for the Israeli company was $110 million in upfront cash payments with the potential for an additional $110 million upon meeting certain commercial milestones.
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Analysts say that Stryker's purchase of a small but fast-growing public company in the complex spine market should help its own struggling spine business.
Stryker is shelling out top dollar to buy Novadaq, a maker of fluorescence imaging technologies that allows surgeons to see blood flow in vessels during surgery in real time.
Orthopedics heavyweight Stryker is leveraging Microsoft's Microsoft HoloLens holographic technology to reimagine the operating room and bring efficiencies to hospitals.
The shift from volume to value is no where more apparent than in the orthopedics specialty where vendors that once obsessed over titanium and steel are now focusing on services to manage the bundled payment era.
As the buzz around robotics grows, J&J 's DePuy Synthes is touting the clinical and economic evidence tied to its non-robotic knee platform to help hospitals navigate the bundled payments era, but will that sway them?
Stryker is launching its Triathlon total knee on its Mako robotic system, reportedly priced at $1 million, at a time of bundled payments and cost consciousness in joint replacement procedures.
Zimmer Biomet just acquired a telerehab startup, RespondWell, to play in a different part of the bundle as it relates to the Comprehensive Care for Joint Replacement program for hip and knee replacements. Stryker is not interested in such technology.
Smart medtech companies are realizing that they have to be partners to hospitals and not simply vendors selling widgets.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
The SurgiCount product has been available for years, but Stryker is now standing by its product in a unique and perhaps rarely confident way. The device company is calling it the SurgiCount Promise.
Washington-based Physio-Control will be integrated into Stryker’s emergency medical systems portfolio.
Neurotechnology, mobility and robotics are the main focuses for Stryker moving forward.
MedReps.com surveyed 1,400 members of the site’s community, who currently work or recently worked in medical sales, to determine which companies are the best to work for overall. Best medical device company: Medtronic. Stryker and Johnson & Johnson ranked second and third. Best pharma company: Johnson & Johnson. Pfizer and Eli Lilly ranked second and […]
Stryker Corp.’s OtisMed unit will pay $80 million in fines because the division distributed its knee replacement surgery devices without regulatory approval in 2009. Stryker said in a statement that the DOJ acknowledged that OtisMed’s criminal conduct “occurred prior to Stryker’s acquisition of OtisMed and without Stryker’s prior knowledge or acquiescence.” Bloomberg says: OtisMed will pay a fine of $34.4 million […]
